Please assess the completion status of the following clinical trial:

Trial Title: A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of endogenous Cushing's syndrome~* Baseline UFC 1.3 to 10 × upper limit of normal (ULN)~* If previous pituitary surgery, participants must be at least 3 months since surgery at the time of screening~* BMI between 18 and 60 kg/m2, inclusive~Exclusion Criteria:~* Pseudo-Cushing's syndrome, cyclic Cushing's syndrome or current iatrogenic Cushing's syndrome~* Candidates for surgical treatment of Cushing's syndrome, unless surgery is not anticipated to occur during the study~* Normal late night salivary cortisol or 24-hr urine free cortisol~* Radiotherapy of the pituitary within 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ATR-101 (Type: EXPERIMENTAL): During the 4-week randomized withdrawal period, eligible subjects will receive ATR-101 at the same dose level being used at the completion of the open-label dose-escalation period.
- Placebo (Type: PLACEBO_COMPARATOR): During the 4-week randomized withdrawal period, eligible subjects will receive a placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.

Based on this trial design, predict the completion outcome and termination type (if applicable).